Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CPIX 
Cumberland Pharmaceuticals Inc (CPIX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: CPIX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $8.5
1 Year Target Price $8.5
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 20.54% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 51.91M USD | Price to earnings Ratio - | 1Y Target Price 8.5 |
Price to earnings Ratio - | 1Y Target Price 8.5 | ||
Volume (30-day avg) 1 | Beta -0.39 | 52 Weeks Range 1.04 - 7.25 | Updated Date 08/29/2025 |
52 Weeks Range 1.04 - 7.25 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.22 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-05 | When - | Estimate - | Actual -0.02 |
Profitability
Profit Margin -6.97% | Operating Margin (TTM) -6.9% |
Management Effectiveness
Return on Assets (TTM) -2.55% | Return on Equity (TTM) -10.89% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 46164693 | Price to Sales(TTM) 1.23 |
Enterprise Value 46164693 | Price to Sales(TTM) 1.23 | ||
Enterprise Value to Revenue 1.07 | Enterprise Value to EBITDA 12.92 | Shares Outstanding 14959900 | Shares Floating 7969607 |
Shares Outstanding 14959900 | Shares Floating 7969607 | ||
Percent Insiders 41.57 | Percent Institutions 24.77 |
Upturn AI SWOT
Cumberland Pharmaceuticals Inc
Company Overview
History and Background
Cumberland Pharmaceuticals Inc. was founded in 1999 and is headquartered in Nashville, Tennessee. The company focuses on developing and commercializing branded prescription products.
Core Business Areas
- Hospital Acute Care: This segment focuses on products used in hospitals, primarily for pain management and other acute conditions.
- Gastroenterology: This segment includes products that address gastrointestinal disorders.
- Dermatology: This segment is focused on products indicated for various dermatological conditions.
Leadership and Structure
The CEO is John N. Mappin. The company has a typical corporate structure with departments for R&D, Sales & Marketing, Finance, and Operations.
Top Products and Market Share
Key Offerings
- Acetadote: An antidote for acetaminophen overdose. Competitors include generic versions of acetylcysteine. Revenue varies based on market demand and hospital contracts, estimated around $20-$30 million annually.
- Caldolor: An intravenous ibuprofen injection for pain and fever. Competitors include other IV NSAIDs and opioids. Revenue estimated to be between $40 and $50 million annually.
- Vibativ: An antibiotic for serious bacterial infections. Competitors include other branded and generic antibiotics. Revenue generation is less compared to other products at under $10 million.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high R&D costs, regulatory hurdles, and intense competition. Focus is on innovation and market access.
Positioning
Cumberland focuses on niche markets and addressing unmet medical needs. It differentiates through targeted products and specialized sales efforts. Competition includes large pharmaceutical companies and generic manufacturers.
Total Addressable Market (TAM)
The TAM for Cumberland's acute care, gastrointestinal, and dermatology products is estimated to be in the billions of dollars. Cumberland targets specific segments within this TAM, representing a smaller, but still significant, market opportunity.
Upturn SWOT Analysis
Strengths
- Niche market focus
- Established product portfolio
- Experienced management team
- Strong hospital relationships
Weaknesses
- Limited financial resources compared to larger competitors
- Reliance on a few key products
- Vulnerability to generic competition
- Relatively small sales force
Opportunities
- Acquisition of complementary products
- Expansion into new therapeutic areas
- Strategic partnerships
- Geographic expansion
Threats
- Generic competition
- Changing regulatory landscape
- Pricing pressures
- Patent expirations
Competitors and Market Share
Key Competitors
- TEVA
- MYL
- PFE
- JNJ
Competitive Landscape
Cumberland faces competition from larger pharmaceutical companies and generic manufacturers. Its competitive advantage lies in its niche market focus and specialized sales efforts.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been uneven, with periods of expansion and contraction.
Future Projections: Future growth depends on successful product launches, acquisitions, and strategic partnerships. Analyst estimates vary.
Recent Initiatives: Recent initiatives include product development, marketing efforts, and cost management programs.
Summary
Cumberland Pharmaceuticals operates in a competitive industry, holding its own with a few core offerings. While it holds a niche positioning, it needs to diversify its product portfolio to reduce its dependency on a small number of products. It has to look out for large pharmaceutical companies entering its niche area as well as generic competitors entering the market. Strategic initiatives such as acquiring new products and geographic expansion could create opportunities for Cumberland.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Industry Publications
Disclaimers:
The data provided is for informational purposes only and should not be considered investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cumberland Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Nashville, TN, United States | ||
IPO Launch date 2009-08-11 | Founder, Chairman, President & CEO Mr. A. J. Kazimi MBA | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 91 | Website https://www.cumberlandpharma.com |
Full time employees 91 | Website https://www.cumberlandpharma.com | ||
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, an injection for the prevention of nausea and vomiting for patients receiving chemotherapy treatment; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It also develops ifetroban, a product candidate that has completed Phase II clinical trials for the treatment of the cardiomyopathy associate with Duchenne muscular dystrophy, hepatorenal syndrome, portal hypertension, and aspirin-exacerbated respiratory disease; and is in Phase II clinical trial for the treatment of systemic sclerosis and idiopathic pulmonary fibrosis. Cumberland Pharmaceuticals Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.